New hope for Tough-to-Treat breast cancer: drug combo trial aims to shrink tumors before surgery

This study is testing if adding a targeted drug called pyrotinib to standard chemotherapy before surgery works better than chemotherapy alone for people with a specific, high-risk type of early breast cancer. It will involve about 160 adults with hormone-positive, HER2-low breast cancer that is at high risk of returning. The main goal is to see if the combination treatment shrinks the tumor more effectively, potentially leading to better long-term outcomes.